15. Why are monoclonal antibody therapies less effective against emerging SARS-CoV-2 variants?(A) Variants replicate slower than antibodies can bind.(B) Mutations in non-spike proteins prevent antibody binding.(C) Antibody production is delayed in vaccinated individuals.(D) Mutations in spike epitopes reduce antibody binding affinity.(E) Monoclonal antibodies degrade too quickly in the bloodstream.